A Leading Producer of Monoclonal Antibodies LEBANON, N.H. , Oct.
17, 2024 /PRNewswire/ -- Bio X Cell, LLC ("BXC" or the "Company"), the world's leading producer of monoclonal antibodies for pre-clinical in vivo research applications, is pleased to announce the appointments of Alan Hirzel and Kevin Ballinger to its Board of Directors. "We are thrilled to welcome Alan Hirzel to the board alongside Kevin Ballinger , who joined earlier this year," said Chris Conway , CEO of Bio X Cell. "Alan and Kevin bring a wealth of experience and industry knowledge to the table, which will serve us well as we execute on BXC's extraordinary strategic growth opportunities following the Company's recent acquisition by Windjammer Capital Investors.
" "Alan's deep domain expertise in the antibody space, and success building out the Abcam platform as its former CEO, will prove invaluable as we scale the Bio X Cell business," said Craig Majernik , Managing Director at Windjammer. "He's a terrific complement to Kevin who, as the former CEO of Aldevron, led that business through a period of significant growth, and during a period of transition from founder to private equity ownership and, ultimately, to a strategic acquirer." "Many of the same value creation levers we were able to capitalize on at Aldevron, I see at Bio X Cell," said Kevin Ballinger .
"It is rare to find a business so well positioned for growth. We've assembled a very capable leadership team to pair with the Company's strong core group.
